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ABSTRACT
Variability in rotavirus gastroenteritis (RVGE) epidemiology can inﬂuence the optimal vaccination
schedule. We evaluated regional trends in the age of RVGE episodes in low- to middle- versus high-
income countries in three continents. We undertook a post-hoc analysis based on efﬁcacy trials of a
human rotavirus vaccine (HRV; RotarixTM, GSK Vaccines), in which 1348, 1641, and 5250 healthy
infants received a placebo in Europe (NCT00140686), Africa (NCT00241644), and Asia (NCT00197210,
NCT00329745). Incidence of any/severe RVGE by age at onset was evaluated by active surveillance
over the ﬁrst two years of life. Severity of RVGE episodes was assessed using the Vesikari-scale. The
incidence of any RVGE in Africa was higher than in Europe during the ﬁrst year of life (2.78% vs.
2.03% per month), but much lower during the second one (0.86% versus 2.00% per month).
The incidence of severe RVGE in Africa was slightly lower than in Europe during the ﬁrst year of life.
Nevertheless, temporal proﬁles for the incidence of severe RVGE in Africa and Europe during the
ﬁrst (1.00% and 1.23% per month) and second (0.53% and 1.13% per month) years of life
were similar to those of any RVGE. Any/severe RVGE incidences peaked at younger ages in Africa vs.
Europe. In high-income Asian regions, severe RVGE incidence (0.31% per month) remained low
during the study. The burden of any RVGE was higher earlier in life in children from low- to middle-
compared with high-income countries. Differing rotavirus vaccine schedules are likely warranted to
maximize protection in different settings.
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Introduction
Rotavirus is a leading cause of severe acute gastroenteritis,
resulting in approximately 450,000 annual deaths among chil-
dren <5 years of age, with almost 90% of these deaths occur-
ring in low-income Asian and African countries.1,2 In children,
the ﬁrst rotavirus infection is generally the most severe, and
subsequent infections result in less serious disease outcomes,
probably because older children have acquired protective
immunity via natural infection.2
Vaccination is considered the most effective strategy to con-
trol the global burden associated with rotavirus gastroenteritis
(RVGE). The World Health Organization (WHO) recommends
inclusion of rotavirus vaccines in all national immunisation pro-
grammes and considers rotavirus vaccination as a priority, par-
ticularly in countries with high RVGE mortality rates.2
Although the WHO recommends that ﬁrst doses of rotavirus
vaccines be administered as early as possible, the previous rec-
ommendations to initiate rotavirus immunisation in children
<15 weeks of age was removed, along with the upper age limit
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restriction, from the new policy in order to optimise coverage.2
However, the removal of both limits of the age restriction do not
emphasize early vaccination, leading to a potentially higher bur-
den of disease in settings with high RVGE incidence in early
infancy and potentially increasing the risk of intussusception.3
Two live, oral, attenuated rotavirus vaccines are globally
available for RVGE prevention: the human rotavirus G1P [8]
strain vaccine RIX4414 (HRV; RotarixTM, GSK Vaccines, Bel-
gium) and a pentavalent, human-bovine reassortant rotavirus
vaccine (RotaTeqTM, Merck & Co, USA). Previous studies have
shown that HRV, which is available in over 100 countries for
immunisation of infants after 6 weeks of age, is immunogenic,
well-tolerated, and effective in preventing severe RVGE.4-11
Since the ﬁrst rotavirus infection in infants is generally the
most severe, it is important to understand regional trends in the
timing of that experience of ﬁrst symptomatic RVGE episode in
order to identify the optimal age for rotavirus vaccination. This
paper presents a post-hoc analysis, which descriptively com-
pares the incidence of RVGE at different timepoints over the
ﬁrst two years of life in low- to middle-income countries (Africa)
with that in high-income countries (Europe and high-income
Asian regions). The analysis was based on data from three ran-
domized, placebo-controlled, multicentre efﬁcacy trials on
HRV, conducted in Europe (NCT00140686), Africa
(NCT00241644), and Asia (NCT00197210 and NCT00329745),
which have been previously presented.9,12-17
Results
Age at ﬁrst vaccination
The majority of children received their ﬁrst HRV or placebo
dose at the age of 2 months in Europe (65.87%), 1 months in
Africa (93.82%), and 3 months in Asia (58.76%) (Table 1).
Incidence of any RVGE episodes by age
In Europe, peaks in incidence of RVGE of similar magnitudes
were observed during the ﬁrst (2.03% at 9–10 months of age)
and second (2.00% at 20–21 months of age) years of life among
unvaccinated children (Fig. 1A). In children who had received
two doses of HRV, incidence of any RVGE episodes remained
low during the entire study (range: 0.00–0.52%).
In Africa, incidence of any RVGE in unvaccinated children
showed a peak in the ﬁrst year of life (2.78% at 5 months of
age) and was lower (range: 0.0–0.86%) in the second year of life
(Fig. 1B). The incidence of any RVGE during the ﬁrst year of
life peaked at 1.83% at 6 months of age in children who had
received two doses of HRV and at 1.12% at 7 months of age in
children who had received three doses of HRV.
In unvaccinated children in the African study, differences in
terms of incidence of any RVGE were observed between coun-
tries. In South Africa, two peaks were observed: a main peak in
the ﬁrst year of life and a lower peak in the second year of life.
In Malawi, where rotavirus is known to circulate year-round,
data were more variable, but there was still a trend for higher
incidence of any RVGE during the ﬁrst year of life.
Comparisons between studies suggest that the incidence
of any RVGE in unvaccinated children was 40% higher in
Africa than in Europe in the ﬁrst year of life, with a higher
incidence of early RVGE (2–5 months of age). In the sec-
ond year of life, the incidence of any RVGE was still high
in Europe, but was much lower in Africa. The incidence of
any RVGE tended to be lower in European children who
had received two doses of HRV than in African children
who had received two or three doses of HRV, especially
during the ﬁrst year of life.
Incidence of severe RVGE episodes by age
In general, the temporal proﬁle for severe RVGE episodes
(a score of 11 in the 20-point Vesikari scale) was similar to
that for any RVGE episode.
In Europe, peaks in incidence of severe RVGE were observed
in the ﬁrst (1.23% at 9 months of age) and second (1.13% at
18 months of age) years of life among unvaccinated infants
reﬂecting the cyclic nature of rotavirus infection in Europe
where rotavirus circulates predominantly during the winter
months (Fig. 2A).
In Africa, the peak in incidence of severe RVGE observed
during the ﬁrst year among unvaccinated infants (1.00% at
8 months of age) was less evident than that observed for any
RVGE (Fig. 2B).
The incidence of severe RVGE in unvaccinated children
seemed comparable in Africa and in Europe in the ﬁrst year of
life, but tended to be higher in Europe than in Africa during
the second year of life. Moreover, ﬁrst severe RVGE episodes
seemed to occur at a younger age in African children. The inci-
dence of severe RVGE was low in vaccinated children in both
the European and the African study.
In Asia, the incidence of severe RVGE during the ﬁrst two
years of life was low among both unvaccinated (range: 0.00–
0.31%) and vaccinated (range: 0.00–0.02%) children (Fig. 2C).
Table 1. Age of the children at the time of ﬁrst vaccination in the European, African and Asian studies (total vaccinated cohort).
Study Group <1 month n (%) 1 month n (%) 2 months n (%) 3 months n (%) 4 months n (%)
European HRV – 230 (8.69) 1743 (65.87) 672 (25.40) 1 (0.04)
Placebo – 123 (9.12) 888 (65.88) 337 (25.00) 0 (0.00)
African HRV-3 D 1 (0.06) 1549 (93.82) 101 (6.12) – –
HRV-2 D 3 (0.18) 1565 (95.02) 79 (4.80) – –
Placebo 2 (0.12) 1544 (94.09) 95 (5.79) – –
Asian HRV – 286 (5.34) 1912 (35.68) 3154 (58.85) 7 (0.13)
Placebo – 252 (4.71) 1943 (36.32) 3143 (58.76) 11 (0.21)
DD dose; HRV D human rotavirus vaccine.
n (%) D number (percentage) of children in the given category.
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Discussion
To maximise their impact, effective vaccines against rotavirus
should be administered early in life and before exposure to the
ﬁrst symptomatic natural infection, which is usually the most
severe. Since rates of exposure to rotavirus vary by geographic
region and socio-economic situation, it is important to under-
stand the incidence of RVGE and the age at which symptomatic
infection occurs in both low- to middle- and high-income
countries.
This analysis showed that the burden of any RVGE was
higher in young children from low- to middle-income African
compared to high-income European countries during the ﬁrst
year of life. Moreover, the peak age of disease was observed in
younger children in Africa versus Europe, in line with previ-
ously reported data.3,18 While the incidence of any RVGE in
unvaccinated children between 2 and 6 months of age was
approximately two times higher in Africa than in Europe, the
opposite tendency was observed during the second year of life,
highlighting the earlier symptomatic infection in Africa. The
lower incidence of any RVGE in the second year of life in
Africa (0.86%) could be explained by the higher rate of natu-
ral immunity to wild-type infection, which is acquired at a
younger age in unvaccinated infants from low- to middle-
income vs. high-income countries.19 These results suggest that
early universal primary immunization may be useful in Europe
and in Africa, while the beneﬁts of any booster dose should be
evaluated in future studies.
In Europe and Africa, the age-distribution of severe RVGE
was similar to that of any RVGE: incidence was higher in Africa
than in Europe during the ﬁrst 2–6 months of age and
decreased during the second year of life in Africa, while peaks
of incidence of similar magnitude were observed during the
ﬁrst and second years in Europe. However, in contrast with
observations made for any RVGE, peaks of incidence of severe
RVGE seemed higher in both the ﬁrst and second years of life
in Europe compared to Africa. A potential explanation for this
observation could be that the really early cases (before two
months of age) are not captured in these studies; this hypothe-
sis is supported by the high IgA positivity rates in Malawi at
enrolment, demonstrating early exposure to wild-type infec-
tion.12 The lower incidence of severe RVGE in Africa could
also be due to differences in intensity of surveillance between
sites, which may have impacted the detection rate. To under-
score whether this is due to differences in case ascertainment
speciﬁc to RVGE or more generalizable, analyses in terms of
all-cause gastroenteritis are needed.
The incidence of severe RVGE observed in Asia ranged
between 0.00% and 0.31% in both vaccinated and unvaccinated
children; the low incidence observed in these three high-income
regions may not correctly reﬂect the situation in the rest of
Asia.15 Indeed, a sub-analysis of the data from Hong Kong
showed that 1.5% (23/1499) of placebo- and 0.1%
(1/1494) of vaccine-recipients had severe RVGE during the ﬁrst
two years of life.13 Moreover, in a previous hospital-based surveil-
lance conducted between 2005 and 2008 in Singapore, the annual
incidence of RVGE hospitalisations (per 1000 Person-year) was
5.40 (95% CI: 4.65, 6.23) in children <1 year of age and 5.77
(95% CI: 5.21, 6.37) in children<2 years of age, with yearly peaks
between January and March.20 The incidence of severe RVGE
Figure 2 Incidence of severe rotavirus gastroenteritis cases by age at onset in (A) Europe (B) Africa and (C) Asia Footnote: Data obtained from the total vaccinated cohort.
DD dose; HRV D human rotavirus vaccine.
Figure 1 Incidence of any rotavirus gastroenteritis cases by age at onset in (A) Europe and (B) Africa Footnote: Data obtained from the total vaccinated cohort. D D dose;
HRVD human rotavirus vaccine.
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was also signiﬁcantly higher in a previous study conducted in
China, where 4.8% (95% CI: 3.8, 5.9) of unvaccinated children
had reported an episode of severe RVGE during the ﬁrst two years
of life.21 The low incidence in the Asia study could reﬂect differ-
ences in ascertainment, particularly in the Singapore sample.
The comparison of results obtained in unvaccinated and
vaccinated children in the low- to middle-income country set-
ting indicates that early vaccination against rotavirus could
decrease the RVGE burden in the ﬁrst year of life, when infants
are the most vulnerable to the rapid onset and outcomes of
symptomatic disease. This is in line with results of previous
studies.5-7,9-11 The WHO recommends the completion of the
immunisation schedule early in infancy; this should especially
be implemented in low- to middle-income countries, where
disease burden is high and occurs early.2 A previous analysis
showed that >30% of children receive their childhood vaccines
later than recommended in most low- and middle-income
countries.22 Unfortunately, this puts the infants in the highest
burden settings at an added disadvantage. Improved timing of
childhood immunisations, along with rotavirus vaccine, and
strengthening of health care systems in developing countries is
urgently needed, as suggested by data from numerous epidemi-
ology studies in low- to middle-income countries.12,23,24
Regarding the timing of vaccination, initiating immunisa-
tion during the neonatal period could provide early protection
and would likely reduce the risk of intussusception.3,25 Previous
studies showed that vaccination with a rhesus rotavirus-based
tetravalent vaccine during the neonatal period triggered good
immune responses and demonstrated efﬁcacy during the ﬁrst
year of life.26,27 Moreover, vaccination with the neonatal RV3
strain during the ﬁrst 7 days of life triggered immune responses
similar to the conventional immunisation schedule.28 However,
before neonatal immunisation can be recommended, the actual
timing for ﬁrst dose and the protection of the vaccine against
disease later in life should be evaluated. However, it has been
suggested that these orally administered, live attenuated vac-
cines might be associated with a waning of immunity. We
know that re-infection in developing countries is common and
is, in general, associated with milder disease.19,29,30 However, a
recent cohort study in India has shown that infants can be
symptomatically infected multiple times, even with a similar
strain.19 If the waning of immunity is true, then a neonatal
schedule is unlikely to be the solution to long-term protection
into the second year of life. Furthermore, we may need to con-
sider alternate immunisation strategies for rotavirus vaccines
that give early protection against severe symptomatic infection
in the ﬁrst few months of life, and longer term protection when
children are still vulnerable to the disease.
This analysis has several strengths, such as the facts that epi-
sodes of any and severe RVG were identiﬁed by active surveil-
lance, captured using a clinical deﬁnition that focused on
hospitalization and rehydration, and graded with the use of the
validated 20-point Vesikari scale. Moreover, we compared
results from three placebo controlled trials with the same end-
points and including children aged between 6 and 20 weeks.
This study has several limitations, such as the fact that it was a
retrospective analysis, differences in case ascertainment might
have occurred between sites, really early cases of RVGE were
not captured because they were excluded per protocol within
the primary evaluation, and duration of the surveillance during
the ﬁrst year of life was different in each study due to variability
in age at ﬁrst dose. Moreover, analysis of data by child-year of
exposition would be needed to address the question of the
importance of seasonality. Indeed, as previously reported for
regions with a temperate climate, a clear seasonality of the rota-
virus epidemiology, with a peak of incidence during the winter,
was observed in Europe and South Africa,2 although rotavirus
does circulate year round in South Africa, albeit at a lower
level.31,32 In contrast, no peak of incidence was observed in
Malawi, where the climate is sub-tropical, and in Asia, where
the incidence of RVGE remained low during the entire study.
In Europe and South-Africa, all infants were recruited within a
limited age range, and most of them shortly before the start of
rotavirus season. Age at the time of RVGE episodes should
therefore not be completely dissociated from the exposure time
to rotavirus. Finally, this study was also limited by the the low
incidence of severe RVGE in Asia, which may be partly due to
a lower case ascertainment in Singapore, where 61.1% of partic-
ipants were enrolled. Other contributing factors could be the
facts that (i) in these three high-income regions the age of onset
of rotavirus diarrhea may be shifted to an older age, (ii) rotavi-
rus incidence peaks every few years in these regions with peri-
ods of relatively low rotavirus circulation between the peaks,
and (iii) admissions to private hospitals might have been
missed by the computerised system used in this trial.
In conclusion, this study showed that the incidence of
any RVGE episodes in unvaccinated children was higher in
Africa than in Europe during the ﬁrst year of life, while
that of severe RVGE seemed comparable in both regions.
During the second year of life, the incidence of any or
severe RVGE in placebo-recipients was lower in Africa. In
high-income regions of Asia, the incidence of severe RVGE
remained very low during the ﬁrst two years of life. Our
results conﬁrmed that vaccination against rotavirus should
be given early in infancy to all children, in particular those
living in low- and middle-income countries, to reduce the
burden of rotavirus disease.
Materials and methods
Study designs
We undertook a post-hoc analysis based on data from three
randomized, placebo-controlled, multicentre efﬁcacy trials on
HRV, which were conducted in Europe (NCT00140686), Africa
(NCT00241644), and Asia (NCT00197210 and NCT00329745).
The results of the primary study objectives, and the inclusion
and exclusion criteria of the study participants have been previ-
ously presented.9,12-17
In the European study, which was conducted between
September 2004 and August 2006, healthy infants aged 6–
14 weeks from the Czech Republic, Finland, France, Germany,
Italy, and Spain were randomized (2:1) to receive two doses of
HRV (N D 2646) or placebo (N D 1348) co-administered with
routine childhood vaccines according to the national plan of each
country. Infants were enrolled between 08 September 2004 and
01 February 2005; 3271 infants (82%) received the ﬁrst dose of
HRV or placebo before the beginning of the annual rotavirus
4 A. D. STEELE ET AL.
D
ow
nl
oa
de
d 
by
 [9
4.1
07
.23
3.2
50
] a
t 2
3:4
1 1
2 J
un
e 2
01
6 
epidemic season, and 723 infants (18%) received the ﬁrst dose
during the ﬁrst rotavirus epidemic season (from December to
May).9
In the African study, which was conducted between October
2005 and January 2009, healthy infants aged 5–10 weeks from
South Africa and Malawi were randomized (1:1:1) to receive
three doses of HRV (N D 1651), a placebo dose followed by
two doses of HRV (N D 1647), or three doses of placebo
(N D 1641) at 6, 10, and 14 weeks of age. In South Africa,
infants were enrolled from October 2005 through January 2006
(cohort 1) and from November 2006 through early February
2007 (cohort 2), and were vaccinated before the anticipated
rotavirus seasons (winter–spring peak).31 In Malawi, where
rotavirus is known to circulate year-round, infants were
enrolled between October 2006 and July 2007.14
In the Asian study, which was conducted between December
2003 and July 2008, healthy infants aged 6–12 weeks from
Hong Kong and Taiwan or aged 11–17 weeks from Singapore
were enrolled between December 2003 and August 2005, and
were randomized (1:1) to receive two doses of HRV
(N D 5250) or placebo (N D 5250) co-administered with rou-
tine childhood vaccines according to each local country regula-
tion. Infants were continuously enrolled and vaccinated before,
during, and after rotavirus seasons.
The three studies were conducted in accordance with Good
Clinical Practice guidelines, the Declaration of Helsinki, and local
rules and regulations of the countries. Parents/guardians of the par-
ticipating infants provided written consent before any study-related
procedure. The study protocols and related documents were
approved by the ethics committee of the individual study centers.
Analysis of the incidence of rotavirus gastroenteritis and
clinical severity.
This post-hoc analysis used data collected between the time
of ﬁrst dose administration and the end of follow-up in the sec-
ond year of life.
RVGE episodes were assessed through active follow-up sur-
veillance. In Europe, weekly or bi-weekly contacts were made
with parents/guardians to inquire about the occurrence of gas-
troenteritis, and any gastroenteritis-related medical care, advice
and hospitalisation. In Africa, active surveillance for gastroen-
teritis episodes was done through weekly visits from the day of
ﬁrst dose until one year of age for children in cohort 1 in South
Africa, and until approximately two years of age for children in
cohort 2 in South Africa and all children in Malawi. In Asia,
where only episodes of severe RVGE were recorded, hospital/
medical facility surveillance was put in place in the study area
to ensure that all gastroenteritis cases requiring hospitalisation
or re-hydration therapy in a medical facility were captured. In
addition, weekly or bi-weekly contacts were made with parents/
guardians/caretakers to determine whether there had been any
admissions to hospitals.
An episode of gastroenteritis was deﬁned as the occurrence
of diarrhea (3 looser than normal stools within a 24 hour
period) with or without vomiting. If there was an interval of
5 symptom-free days between two gastroenteritis episodes,
they were considered as different episodes. Stool samples were
collected during each episode of gastroenteritis and were ana-
lyzed for rotavirus using enzyme-linked immunosorbent assay
(ELISA; RotaCloneTM assay, Meridian Biosciences, USA).
For each suspected gastroenteritis episode in the European
and African studies, and each severe gastroenteritis episode in
the Asian study, a diary card was completed daily. The following
information was recorded: axillary/rectal temperature, number of
vomiting episodes and looser than normal stools, rehydration or
other medication given during the gastroenteritis episode, medi-
cal attention sought, and behavioral symptoms.
The severity of RVGE episodes was assessed using the 20-
point Vesikari scale, where a score of 11 was considered as
severe.33 The incidence of RVGE was calculated as the number
of children with RVGE multiplied by 100 and divided by the
number of children at risk. The incidence of any and severe
RVGE was evaluated in the different geographical regions by
age at onset over the ﬁrst two years of life. The results are pre-
sented per age group: children aged 1 – <2 months at onset
were included in the 1 month age group, children aged 2 –
<3 months at onset in the 2 months age group, etc.
Statistical analysis
All analyses were performed on the total vaccinated cohorts,
including children who received 1 dose of HRV or placebo.
All comparisons of RVGE incidence between the different
regions and age groups were descriptive.
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